Literature DB >> 12418933

Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

Wiepke Cahn1, Hilleke E Hulshoff Pol, Elleke B T E Lems, Neeltje E M van Haren, Hugo G Schnack, Jeroen A van der Linden, Patricia F Schothorst, Herman van Engeland, René S Kahn.   

Abstract

BACKGROUND: Imaging studies of patients with schizophrenia have demonstrated that brain abnormalities are largely confined to decreases in gray matter volume and enlargement of the lateral and third ventricles. Global gray matter volume has been reported to progressively decrease in childhood-onset and chronic schizophrenia. Global gray matter volumes have not been examined longitudinally in patients with first-episode schizophrenia. One would expect global gray matter to decrease progressively, particularly in first-episode patients, because clinical deterioration is greatest in the early stages of the disease.
METHODS: Patients with first-episode schizophrenia who had taken antipsychotic medication for 0 to 16 weeks (n = 34) and matched healthy comparison subjects (n = 36) were included in the study. For all subjects, magnetic resonance imaging scans of the whole brain were obtained at inclusion and after 1 year (mean [SD], 12.7 [1.1] months). Outcome was measured 2 years after inclusion. To compare morphological changes over time between patients and healthy comparison subjects, multiple repeated-measures analyses of variance were conducted with intracranial volume as a covariate. Outcome and cumulative antipsychotic medication were related to changes in patients' brain volumes.
RESULTS: Total brain volume (-1.2%) and gray matter volume of the cerebrum (-2.9%) significantly decreased and lateral ventricle volume significantly increased (7.7%) in patients. The decrease in global gray matter volume significantly correlated with outcome and, independently of that, with higher cumulative dosage of antipsychotic medication.
CONCLUSIONS: The loss of global gray matter in schizophrenia is progressive, occurs at an early stage of the illness, and is related to the disease process and antipsychotic medication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12418933     DOI: 10.1001/archpsyc.59.11.1002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  83 in total

Review 1.  [Changes in brain structure caused by neuroleptic medication].

Authors:  H Scherk; P Falkai
Journal:  Nervenarzt       Date:  2004-11       Impact factor: 1.214

Review 2.  Differential aging of the brain: patterns, cognitive correlates and modifiers.

Authors:  Naftali Raz; Karen M Rodrigue
Journal:  Neurosci Biobehav Rev       Date:  2006-08-17       Impact factor: 8.989

3.  Unifying the analyses of anatomical and diffusion tensor images using volume-preserved warping.

Authors:  Dongrong Xu; Xuejun Hao; Ravi Bansal; Kerstin J Plessen; Weidong Geng; Kenneth Hugdahl; Bradley S Peterson
Journal:  J Magn Reson Imaging       Date:  2007-03       Impact factor: 4.813

4.  Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study.

Authors:  Motoaki Nakamura; Dean F Salisbury; Yoshio Hirayasu; Sylvain Bouix; Kilian M Pohl; Takeshi Yoshida; Min-Seong Koo; Martha E Shenton; Robert W McCarley
Journal:  Biol Psychiatry       Date:  2007-06-27       Impact factor: 13.382

5.  CSF sub-compartments in relation to plasma osmolality in healthy controls and in patients with first episode schizophrenia.

Authors:  Handan Gunduz-Bruce; Katherine L Narr; Ralitza Gueorguieva; Arthur W Toga; Philip R Szeszko; Manzar Ashtari; Delbert G Robinson; Serge Sevy; John M Kane; Robert M Bilder
Journal:  Psychiatry Res       Date:  2007-03-29       Impact factor: 3.222

Review 6.  The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia.

Authors:  Lynn E DeLisi
Journal:  Schizophr Bull       Date:  2008-02-08       Impact factor: 9.306

Review 7.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

8.  Morphometric brain abnormalities in schizophrenia in a population-based sample: relationship to duration of illness.

Authors:  Päivikki Tanskanen; Khanum Ridler; Graham K Murray; Marianne Haapea; Juha M Veijola; Erika Jääskeläinen; Jouko Miettunen; Peter B Jones; Edward T Bullmore; Matti K Isohanni
Journal:  Schizophr Bull       Date:  2008-11-17       Impact factor: 9.306

Review 9.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

Review 10.  The forthcoming revision of the diagnostic and classificatory system: perspectives based on the European psychiatric tradition.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.